Movers and SHAKERS
PDS Biotechnology Corp (PDSB)
Moving Forward With Clinical Milestones On The Horizon
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is primarily engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Significant Data Was Presented In 2Q21. PDS Biotechnology reported 2Q21 loss of $0.6 million or $(0.03) per share. Importantly, interim Phase 2 data from the lead trial for PDS0101 presented at the ASCO conference showed strong indications of efficacy. Additional data from this PDS0101 trial and two other Phase 2 trials are expected to be announced around 4Q/1H22.
Increased Cash Allows Clinical Trials To Move Forward. During 2Q21, the company completed an offering that raised about $52 million in gross proceeds. Cash on hand at June 30, 2021 was $74.7 million. This gives the company sufficient operating cash to continue current operations and new clinical trials. Two additional Versamune platform products, PDS102 and PDS103, are expected to move to clinical ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.